Importer of Controlled Substances; Notice of Application, 160 [E9-31165]
Download as PDF
<![CDATA[
160
Federal Register / Vol. 75, No. 1 / Monday, January 4, 2010 / Notices
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
pwalker on DSK8KYBLC1PROD with NOTICES
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on
November 5, 2009, Mylan Technologies
Inc., 110 Lake Street, Saint Albans,
Vermont 05478, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in schedule
II:
NUCLEAR REGULATORY
COMMISSION
Dated: December 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–31165 Filed 12–31–09; 8:45 am]
In the Matter of: Certain Licensees
Requesting Unescorted Access to
Radioactive Material; Order Imposing
Trustworthiness and Reliability
Requirements for Unescorted Access
to Certain Radioactive Material
(Effective Immediately)
BILLING CODE 4410–09–P
I
OFFICE OF NATIONAL DRUG
CONTROL POLICY
Paperwork Reduction Act; 30-Day
Notice
AGENCY: Office of National Drug Control
Policy.
The Office of National Drug Control
Policy (ONDCP) proposes the collection
of information concerning arrestee drug
use. ONDCP invites interested persons
to submit comments to the Office of
Drug
Schedule
Management and Budget (OMB)
Methylphenidate (1724) ................
II regarding any aspect of this proposed
Fentanyl (9801) ............................
II effort.
Type of Information Collection: New
The company plans to import the
collection.
listed controlled substances for
Title: Arrestee Drug Abuse Monitoring
analytical research and clinical trials.
(ADAM II) Program Questionnaire.
Any bulk manufacturer who is
presently, or is applying to be,
Use: The information will support
registered with DEA to manufacture
statistical trend analysis.
such basic class of controlled substance
Frequency: Ten sites will each
may file comments or objections to the
conduct two cycles of surveys from 250
issuance of the proposed registration
and may, at the same time, file a written arrestees per cycle.
Annual Number of Respondents:
request for a hearing on such
application pursuant to 21 CFR 1301.43, 5000.
and in such form as prescribed by 21
Total Annual Responses: 5000.
CFR 1316.47.
Average Burden per Response: 25
Any such comments or objections
minutes.
should be addressed, in quintuplicate,
to the Drug Enforcement
Total Annual Hours: 2,083.
Administration, Office of Diversion
Send comments to John Kraemer,
Control, Federal Register Representative
OMB Desk Officer for ONDCP, New
(ODL), 8701 Morrissette Drive,
Executive Office Building, Room 10235,
Springfield, Virginia 22152; and must be
Washington, DC 20503. Comments must
filed no later than February 3, 2010.
be received within 30 days. Request
This procedure is to be conducted
additional information by facsimile
simultaneously with, and independent
transmission to (202) 395–6562,
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted attention: Robert Cohen, ONDCP, Office
of Research and Data Analysis.
in a previous notice published in the
Federal Register on September 23, 1975,
Dated: December 29, 2009.
(40 FR 43745–46), all applicants for
Daniel R. Petersen,
registration to import a basic class of
Deputy General Counsel.
any controlled substance in schedule I
[FR Doc. E9–31132 Filed 12–31–09; 8:45 am]
or II are, and will continue to be,
BILLING CODE 3180–02–P
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
VerDate Nov<24>2008
17:11 Dec 31, 2009
Jkt 220001
[NRC–2009–0577; EA–09–293]
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
The Licensees identified in
Attachment 1 1 to this Order hold
licenses issued in accordance with the
Atomic Energy Act (AEA) of 1954, as
amended, by the U.S. Nuclear
Regulatory Commission (NRC or
Commission) or an Agreement State,
authorizing them to perform services on
devices containing certain radioactive
material for customers licensed by the
NRC or an Agreement State to possess
and use certain quantities of the
radioactive materials listed in
Attachment 2 to this Order. Commission
regulations at 10 CFR 20.1801 or
equivalent Agreement State regulations
require Licensees to secure, from
unauthorized removal or access,
licensed materials that are stored in
controlled or unrestricted areas.
Commission regulations at 10 CFR
20.1802 or equivalent Agreement State
regulations require Licensees to control
and maintain constant surveillance of
licensed material that is in a controlled
or unrestricted area and that is not in
storage.
II
Subsequent to the terrorist events of
September 11, 2001, the NRC issued
immediately effective security Orders to
NRC and Agreement State Licensees
under the Commission’s authority to
protect the common defense and
security of the nation. The Orders
required certain manufacturing and
distribution (M&D) Licensees to
implement Additional Security
Measures (ASMs) for the radioactive
materials listed in Attachment 2 to this
Order (the radionuclides of concern), to
supplement the existing regulatory
requirements. The ASMs included
requirements for determining the
trustworthiness and reliability of
individuals that require unescorted
access to the radionuclides of concern.
Section 652 of the Energy Policy Act of
2005, which became law on August 8,
2005, amended Section 149 of the AEA
to require fingerprinting and a Federal
Bureau of Investigation (FBI)
1 Attachment 1 contains sensitive information
and will not be released to the public.
E:\FR\FM\04JAN1.SGM
04JAN1
]]>Agencies
[Federal Register Volume 75, Number 1 (Monday, January 4, 2010)]
[Notices]
[Page 160]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-31165]
[[Page 160]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on November 5, 2009, Mylan Technologies Inc., 110 Lake Street,
Saint Albans, Vermont 05478, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as an importer of the
basic classes of controlled substances listed in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Methylphenidate (1724)....................................... II
Fentanyl (9801).............................................. II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
analytical research and clinical trials.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43, and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than February 3, 2010.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 43745-46), all
applicants for registration to import a basic class of any controlled
substance in schedule I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: December 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-31165 Filed 12-31-09; 8:45 am]
BILLING CODE 4410-09-P
